Present and prospective clinical therapeutic regimens for Alzheimer's disease

Mustafa M. Husain, Kenneth Trevino, Haroon Siddique, Shawn M. McClintock

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is an incurable neurodegenerative disorder that produces cognitive impairments that increase in severity as the disease progresses. The clinical symptoms are related to the presence of neuritic plaques and neurofibrillary tangles in the cerebral cortex which represent the pathophysiological hallmarks of AD. The debilitating nature of the disease can result in clinical burden for the patient, emotional strain for those that care for patients with Alzheimer's, and significant financial burden to society. The goals of current treatments, such as cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist, are to reduce the severity or slow the progression of cognitive symptoms. Although these treatments have demonstrated modest clinical benefit, they are unable to prevent, prohibit, or reverse the underlying pathophysiology of AD. Considerable progress has been made toward the development of disease-modifying treatments. Treatments currently under development mainly target the production, aggregation, and removal of existing amyloid β-peptide aggregates which are believed to instigate the overall development of the neuropathology. Additional strategies that target tau pathology are being studied to promote neural protection against AD pathology. The current research has continued to expand our knowledge toward the development of disease modifying Alzheimer's therapies; however, no specific treatment strategy capable of demonstrating empirical efficacy and safety has yet to emerge.

Original languageEnglish (US)
Pages (from-to)765-777
Number of pages13
JournalNeuropsychiatric Disease and Treatment
Volume4
Issue number4
StatePublished - 2008

Fingerprint

Alzheimer Disease
Therapeutics
Pathology
Neurobehavioral Manifestations
Neurofibrillary Tangles
Cholinesterase Inhibitors
Amyloid Plaques
N-Methyl-D-Aspartate Receptors
Amyloid
Neurodegenerative Diseases
Cerebral Cortex
Patient Care
Safety
Peptides
Research

Keywords

  • Alzheimer's disease
  • Current treatments
  • Disease-modifying therapies
  • Pathophysiology

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Present and prospective clinical therapeutic regimens for Alzheimer's disease. / Husain, Mustafa M.; Trevino, Kenneth; Siddique, Haroon; McClintock, Shawn M.

In: Neuropsychiatric Disease and Treatment, Vol. 4, No. 4, 2008, p. 765-777.

Research output: Contribution to journalArticle

@article{f6c8e5f2618046898c95533888176f18,
title = "Present and prospective clinical therapeutic regimens for Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is an incurable neurodegenerative disorder that produces cognitive impairments that increase in severity as the disease progresses. The clinical symptoms are related to the presence of neuritic plaques and neurofibrillary tangles in the cerebral cortex which represent the pathophysiological hallmarks of AD. The debilitating nature of the disease can result in clinical burden for the patient, emotional strain for those that care for patients with Alzheimer's, and significant financial burden to society. The goals of current treatments, such as cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist, are to reduce the severity or slow the progression of cognitive symptoms. Although these treatments have demonstrated modest clinical benefit, they are unable to prevent, prohibit, or reverse the underlying pathophysiology of AD. Considerable progress has been made toward the development of disease-modifying treatments. Treatments currently under development mainly target the production, aggregation, and removal of existing amyloid β-peptide aggregates which are believed to instigate the overall development of the neuropathology. Additional strategies that target tau pathology are being studied to promote neural protection against AD pathology. The current research has continued to expand our knowledge toward the development of disease modifying Alzheimer's therapies; however, no specific treatment strategy capable of demonstrating empirical efficacy and safety has yet to emerge.",
keywords = "Alzheimer's disease, Current treatments, Disease-modifying therapies, Pathophysiology",
author = "Husain, {Mustafa M.} and Kenneth Trevino and Haroon Siddique and McClintock, {Shawn M.}",
year = "2008",
language = "English (US)",
volume = "4",
pages = "765--777",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "4",

}

TY - JOUR

T1 - Present and prospective clinical therapeutic regimens for Alzheimer's disease

AU - Husain, Mustafa M.

AU - Trevino, Kenneth

AU - Siddique, Haroon

AU - McClintock, Shawn M.

PY - 2008

Y1 - 2008

N2 - Alzheimer's disease (AD) is an incurable neurodegenerative disorder that produces cognitive impairments that increase in severity as the disease progresses. The clinical symptoms are related to the presence of neuritic plaques and neurofibrillary tangles in the cerebral cortex which represent the pathophysiological hallmarks of AD. The debilitating nature of the disease can result in clinical burden for the patient, emotional strain for those that care for patients with Alzheimer's, and significant financial burden to society. The goals of current treatments, such as cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist, are to reduce the severity or slow the progression of cognitive symptoms. Although these treatments have demonstrated modest clinical benefit, they are unable to prevent, prohibit, or reverse the underlying pathophysiology of AD. Considerable progress has been made toward the development of disease-modifying treatments. Treatments currently under development mainly target the production, aggregation, and removal of existing amyloid β-peptide aggregates which are believed to instigate the overall development of the neuropathology. Additional strategies that target tau pathology are being studied to promote neural protection against AD pathology. The current research has continued to expand our knowledge toward the development of disease modifying Alzheimer's therapies; however, no specific treatment strategy capable of demonstrating empirical efficacy and safety has yet to emerge.

AB - Alzheimer's disease (AD) is an incurable neurodegenerative disorder that produces cognitive impairments that increase in severity as the disease progresses. The clinical symptoms are related to the presence of neuritic plaques and neurofibrillary tangles in the cerebral cortex which represent the pathophysiological hallmarks of AD. The debilitating nature of the disease can result in clinical burden for the patient, emotional strain for those that care for patients with Alzheimer's, and significant financial burden to society. The goals of current treatments, such as cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist, are to reduce the severity or slow the progression of cognitive symptoms. Although these treatments have demonstrated modest clinical benefit, they are unable to prevent, prohibit, or reverse the underlying pathophysiology of AD. Considerable progress has been made toward the development of disease-modifying treatments. Treatments currently under development mainly target the production, aggregation, and removal of existing amyloid β-peptide aggregates which are believed to instigate the overall development of the neuropathology. Additional strategies that target tau pathology are being studied to promote neural protection against AD pathology. The current research has continued to expand our knowledge toward the development of disease modifying Alzheimer's therapies; however, no specific treatment strategy capable of demonstrating empirical efficacy and safety has yet to emerge.

KW - Alzheimer's disease

KW - Current treatments

KW - Disease-modifying therapies

KW - Pathophysiology

UR - http://www.scopus.com/inward/record.url?scp=52649134454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649134454&partnerID=8YFLogxK

M3 - Article

C2 - 19043521

AN - SCOPUS:52649134454

VL - 4

SP - 765

EP - 777

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 4

ER -